Fiche personne


Territoire

Bourgogne

Statut

Hospitalo-Universitaire

Recherche

Expertises :
- Clinique:Pharmacie

Projets


Voir plus

Publications


Co-targeting TGF-β and PD-L1 sensitizes triple-negative breast cancer to experimental immunogenic cisplatin-eribulin chemotherapy doublet.

Kalfeist L, Ledys F, Petit S, Poirrier C, Kada Mohammed S, Galland L, Derangère V, Ilie A, Rageot D, Aucagne R, Bellaye PS, Truntzer C, Thibaudin M, Rialland M, Ghiringhelli F, Limagne E, Ladoire S

J Clin Invest. 2025 07 1;135(13):

Deciphering dual clinical entities associated with TP53 pathogenic variants: Insights from 53,085 HBOC panel analyses in French laboratories.

Kasper E, Boulouard F, Basset N, Golmard L, Sassi H, Bouvignies E, Branchaud M, Charbonnier C, Parodi N, Rolain M, Albuisson J, Al Saati A, Benusiglio P, Berthet P, Bidart M, Bonnet C, Bouras A, Boutry-Kryza N, Brayotel F, Bubien V, Buisson A, Castéra L, Caron O, Colas C, Coulet F, Delnatte C, Derangère V, Fievet A, Garrec C, Gauthier-Villars M, Gay-Bellile M, Goussot V, le Gall J, Lepage M, Lokchine A, Perrier A, Rouleau E, Sevenet N, Stoppa-Lyonnet D, Ravel JM, Perre PV, Vaur D, Vilquin P, Bougeard G, Baert-Desurmont S, Thery JC, Houdayer C

Int J Cancer. 2025 06 11;:

Exploring the role of ESR1 mutations in metastatic hormone receptor-positive breast cancer T cell immune surveillance disruption.

Lopez M, Spehner L, André F, Viot J, Seffar E, Marguier A, Curtit E, Meynard G, Dobi E, Ladoire S, Boidot R, Loyon R, Derangere V, Bidard FC, Borg C, Mansi L, Kroemer M

Breast Cancer Res. 2025 02 7;27(1):19

Voir plus